DC Circ. Upholds FTC's Pharma Patent Rules
A D.C. Circuit panel on Tuesday rejected a pharmaceutical industry group's challenge of a Federal Trade Commission rule requiring disclosure of more exclusive patent licenses for approval under federal merger law,...To view the full article, register now.
Already a subscriber? Click here to view full article